Synergy Pharmaceuticals' Plecanatide Phase 2b Trial in IBS-C Reaches Enrollment Halfway Mark

Published: Jul 17, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq: SGYP), a developer of new drugs to treat gastrointestinal diseases and disorders, today announced that it has reached the halfway mark for total enrollment in its ongoing plecanatide Phase 2b clinical trial in patients with irritable bowel syndrome with constipation (IBS-C). The study is being conducted at 70 sites in the United States and is scheduled to include 350 patients with IBS-C. Over 600 patients have been screened to date and 180 have been enrolled. The first patient was dosed on December 27, 2012 and Synergy anticipates completing enrollment in the fourth quarter of 2013 and reporting topline data in the first quarter of 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news